BRCA2

Biomarkers

BRCA2 is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
BRCA2 pathogenic variants	Germline Variant	22	50
BRCA2 oncogenic variants	Somatic Variant	16	36

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
FDA (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
FDA (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
EMA (1) FDA (2) HSE (2)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (2) FDA (2) HSE (1)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Rucaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
EMA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (2) HSE (2)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Rucaparib
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
EMA (1) HSE (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone